CTRI/2021/06/033962已完成3 期
A Multicenter, Double Blind, Double Dummy, Randomized, Parallel - Group, Three Arm, Phase III, Active Controlled Comparative Study to Assess Efficacy and Safety of Fixed Dose Combination of Dapagliflozin and Sitagliptin Phosphate Tablets in Comparison to Sitagliptin Phosphate Tablets as an add on to Metformin in Patients with Type 2 Diabetes Mellitus.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 389
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Patients of either gender, aged 18 to 65 years (both inclusive) and ready to give written informed consent to participate in the study at the time of screening
- •2)Patients with diagnosis of type 2 diabetes mellitus
- •3)Patients along with diet and exercise control, additionally on stable total daily dose of Metformin IR (1500-2000 mg) as monotherapy for at least 08 weeks prior to screening
- •4)Patients with HbA1c greater than equal to 8 % and less than equal to 11 % at screening
- •5)Patients with BMI less than equal to 45.0 kg/ m2 at screening
- •6)Women of childbearing potential must have a negative urine pregnancy test prior to study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication (such contraception may include hormonal birth control e.g., combined estrogen and progestogen containing [oral, intravaginal, or transdermal] or progesterone only [oral, injectable, or implantable] hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone releasing system OR bilateral tubal occlusion, vasectomized partner, or total sexual abstinence)
- •[Note: Women with childbearing potential are defined as: those who are not (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal. Post-menopausal woman will be defined as: Woman not using hormonal replacement therapy and have had at least 12 continuous months of natural (spontaneous) amenorrhea and be greater than 45 years of age.]
排除标准
- •1.Patients diagnosed with type 1 diabetes, diabetes insipidus, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g. Cushing syndrome or acromegaly- associated diabetes)
- •2.Patients with Fasting Blood Glucose (FBG) greater than equal to 270 mg/dl at screening (if required, measurement can be repeated and confirmed within 7 days)
- •3.Patients with history of hypersensitivity to any of the study drug or to drugs of similar chemical classes (e.g. sulphonamide) or to any of its excipients
- •4.Patients with administration of any therapy for diabetes, other than Metformin during the 8 weeks prior to screening
- •5.Patients with history of taking any weight loss medications within 3 months prior to randomization
- •6.Patients planning to take any anti-diabetic drugs or weight loss drugs other than study drugs or rescue medication during the study
- •7.Treatment with glucocorticoids equivalent to oral prednisolone greater than equal to 10 mg (betametasone greater than equal to 1.2 mg, dexamethasone greater than equal to 1.5 mg, hydrocortisone greater than equal to 40 mg) per day within 30 days prior to randomization; topical, nasal or inhaled corticosteroids are allowed
- •8.Patients with history of HIV and/or HBV and/ or HCV
- •9.Patients having significant renal (eGFR below 45 mL/min/1.73 m2) or hepatic impairment (AST and ALT greater than 3 x ULN)
- •10.Patients taking loop diuretics within one week prior to screening or planning to take during the study
- •11.Patients suffering with end-stage renal disease or on dialysis
- •12.Any condition (e.g. infection, trauma, surgery) which require insulin therapy at the time of screening or during the study period. Short term use i.e. ââ?°Â¤ 7 days will be allowed.
- •13.History of bariatric surgery (i.e., any surgery to treat obesity; for example, gastric banding or procedures that involve bypassing or transposing sections of the small intestine). History of liposuction is allowed
- •14.Patients having history of acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis, pancreatitis or hyperosmolar state (including coma)
- •15.Patients having history or currently suffering with severe and disabling arthralgia
- •16.Patients who are lactose intolerant
- •17.Patients suffering from severe urinary tract infections (e.g. urosepsis, pyelonephritis), necrotizing fasciitis of the Perineum (Fournierââ?¬•s Gangrene), intravascular volume contraction and/ or female genital mycotic infections prior to 6 months from screening.
- •18.Patients having history or currently suffering with bullous pemphigoid requiring hospitalization
- •19.Patients with history of Myocardial infarction, Coronary artery bypass surgery or percutaneous coronary intervention, stroke or transient ischemic attack prior to 6 months from screening
- •20.Patients with history of Unstable angina prior to 3 months from screening
- •21.Patients with history of Sustained and clinically relevant ventricular arrhythmia
- •22.Any of the following ECG abnormalities:
- •-Second or third degree AV block without a pacemaker
- •-Long QT syndrome or QTc greater than 500ms
- •23.Patients having history or currently suffering with serious allergic and hypersensitivity reactions such as anaphylaxis, angioedema and exfoliative skin conditions including Stev
研究者
相似试验
进行中（未招募）
不适用
ot applicableEUCTR2010-022971-79-PLHelsinn Healthcare SA660
进行中（未招募）
不适用
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsEvaluate the efficacy of a single palonosetron IV dose to prevent postoperative nausea and vomiting through 24 hours.Evaluate the safety and tolerability of IV palonosetron in pediatric patients.MedDRA version: 13.1Level: LLTClassification code 10036238Term: Postoperative vomitingSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 13.1Level: LLTClassification code 10036285Term: Postoperative nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2010-022971-79-HUHelsinn Healthcare SA660
进行中（未招募）
不适用
ot applicablePostoperative nausea and vomiting (PONV)MedDRA version: 14.0Level: LLTClassification code 10036238Term: Postoperative vomitingSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 14.0Level: LLTClassification code 10036285Term: Postoperative nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2010-022971-79-CZHelsinn Healthcare SA660
进行中（未招募）
不适用
A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement surgery - DRIVEprevention of VTE in patients undergoing elective total hip replacement surgeryMedDRA version: 8.1Level: LLTClassification code 10049909EUCTR2006-000152-41-CZsanofi-aventis recherche & developpement1,020
进行中（未招募）
不适用
A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement surgery - DRIVEprevention of VTE in patients undergoing elective total hip replacement surgeryMedDRA version: 8.1Level: LLTClassification code 10049909EUCTR2006-000152-41-FIsanofi-aventis recherche développement1,020